AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
PathAI vs Tempus AI

VS
PathAI official logo and brand icon

PathAI

Enterprise
Visit WebsiteFull Review
Tempus AI official logo and brand icon

Tempus AI

Enterprise
Visit WebsiteFull Review

Verdict by Category

Detailed category analysis is not available for this comparison.
View PathAI View Tempus AI
Feature & Spec Matrix

Detailed Comparison25 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features
Feature / Spec
PathAI
PathAI
Tempus AI
Tempus AI
Pricing Model
EnterpriseAI pathology solutions for biopharma — Custom enterprise partnership agreements only
EnterpriseGenomic sequencing, clinical data analytics, and precision medicine AI — Custom institutional agreements for healthcare systems and life sciences
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
No free plan — enterprise and biopharma contracts only; acquired by Roche in May 2026
No free plan — genomic tests ordered by physicians; enterprise and biopharma data partnerships via sales
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Hospital pathology labs and biopharma companies needing AI-powered digital pathology for oncology diagnostics, companion diagnostic development, and clinical trial tissue analysis
Oncologists, health systems, and biopharma companies needing AI-powered genomic profiling, precision medicine insights, clinical trial matching, and drug development data
Enterprise & Scalability
Difference
HIPAA compliant, CAP/CLIA certified lab services, FDA 510k cleared algorithms, SOC 2 Type II, full enterprise LIS/PACS integration, dedicated implementation and scientific support, biopharma research service contracts, and 450+ pathologist annotation network
CLIA-certified genomics laboratory, CAP accredited, HIPAA compliant, SOC 2 Type II, de-identified patient data network of 7M+ records, EHR integration via HL7/FHIR, biopharma licensing agreements, and enterprise analytics platform with dedicated clinical account management
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
AISight — cloud-native digital pathology image management, analysis, and collaboration platform
Difference
PathAI Advantage
Not listed
20+ FDA-cleared and research-grade AI algorithms for oncology and liver disease
Difference
PathAI Advantage
Not listed
32.5M+ expert pathologist annotations — one of the largest training datasets in pathology AI
Difference
PathAI Advantage
Not listed
AIM-HER2 Breast Cancer algorithm for automated HER2 scoring with aMIL heatmaps
Difference
PathAI Advantage
Not listed
PathExplore panel of human interpretable features (HIFs) for tumor microenvironment research
Difference
PathAI Advantage
Not listed
Companion diagnostics development in partnership with major pharma companies
Supported
Supported
CLIA-certified lab services for biopharma clinical trial tissue analysis
Supported
Supported
Whole slide image (WSI) management with scanner-neutral compatibility
Difference
PathAI Advantage
Not listed
Acquired by Roche in May 2026 — now backed by global diagnostic infrastructure
Difference
PathAI Advantage
Not listed
Partnerships with Moffitt Cancer Center, University Hospital Zurich, Bristol-Myers Squibb, and Merck
Difference
PathAI Advantage
Not listed
Comprehensive genomic profiling — solid tumor (xT), germline (xG), RNA (xR), liquid biopsy (xF), and expression (xE) testing
Difference
Not listed
Tempus AI Advantage
Multimodal data platform with 7M+ de-identified patient records across clinical, molecular, and imaging data
Difference
Not listed
Tempus AI Advantage
Tempus One — AI clinical assistant for real-time treatment insights and literature synthesis at point of care
Difference
Not listed
Tempus AI Advantage
Neuropsychiatry panel for pharmacogenomics and psychiatric medication response prediction
Difference
Not listed
Tempus AI Advantage
Cardiology ECG analysis AI for arrhythmia and cardiac condition detection
Difference
Not listed
Tempus AI Advantage
Algos platform for population health analytics across health system patient cohorts
Difference
Not listed
Tempus AI Advantage
CLIA-certified lab with CAP accreditation for clinical-grade genomic report delivery
Difference
Not listed
Tempus AI Advantage
Publicly traded (NASDAQ: TEM) — founded 2015, 3,800+ employees, $8.79B total raised
Difference
Not listed
Tempus AI Advantage
PathAI icon

PathAI Pros & Cons

Pros

  • Acquired by Roche (May 2026) — now backed by the world's largest diagnostics company
  • 32.5M+ expert annotations — one of the world's largest pathology AI training datasets
  • 20+ AI algorithms covering oncology, liver disease, and tumor microenvironment analysis
  • AISight is scanner-neutral — works with Leica, Hamamatsu, Philips scanners with FDA clearance
  • CLIA-certified lab services for biopharma clinical trial support
  • Partnerships with BMS, Merck, Moffitt Cancer Center, and University Hospital Zurich
  • First AI pathology company recognized as a leader in CB Insights Digital Pathology market map

Cons

  • Acquired by Roche in May 2026 — future product roadmap and independent operations may change
  • Enterprise and biopharma-focused — not accessible to independent pathologists or small labs
  • No self-serve pricing or trial — all engagements are through enterprise procurement
  • Requires digital pathology infrastructure (scanners, storage, LIS integration)
  • Integration complexity for labs not yet on digital pathology workflows
Tempus AI icon

Tempus AI Pros & Cons

Pros

  • Publicly traded (NASDAQ: TEM) — one of the most credible precision medicine AI companies
  • 7M+ de-identified patient records — one of the world's largest clinical-molecular datasets
  • Comprehensive genomic testing across 6 test types covering all major oncology applications
  • Tempus One AI provides real-time clinical insights at the point of care
  • TIME Trial dramatically improves clinical trial matching and enrollment rates
  • 3,800+ employees and $8.79B total capital raised since founding
  • Expanding beyond oncology into neuropsychiatry, cardiology, and infectious disease

Cons

  • Enterprise and institutional pricing — not accessible to individual clinicians or small practices
  • Focused primarily on oncology and genomics — not a general-purpose clinical AI tool
  • Genomic test turnaround requires laboratory processing time
  • Data platform access and licensing requires formal agreements
  • Some AI insights require institutional genomic data infrastructure to fully leverage
Head-to-Head Battle Cards

Popular Comparisons

Direct feature matrices, pricing breakdowns, and real-world benchmark duels

All AI Healthcare Tools comparisons
Tempus AI vs Insilico Medicine Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Tempus AI and Insilico Medicine in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
PathAI vs Abridge Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between PathAI and Abridge in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Tempus AI vs Atomwise Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Tempus AI and Atomwise in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Tempus AI vs Nabla Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Tempus AI and Nabla in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare